Key result
Endogenous L1 retroelements are hypothesized to drive systemic lupus erythematosus pathogenesis by producing immunogenic proteins that activate cytosolic DNA sensors and type I interferon production.
Why the study?
The etiology of systemic lupus erythematosus remains elusive, prompting a review of the support for and gaps in the hypothesis that endogenous L1 retrotransposons contribute to its pathogenesis.
This review proposes that dysregulated L1 retrotransposons act as endogenous viral-like triggers in SLE, offering a novel model for its pathogenesis and potential therapeutic targets.
Hypothesis-generating for L1 retroelements in SLE; leaves open validation as therapeutic targets.
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. While its etiology remains elusive, current understanding suggests a multifactorial process with contributions by genetic, immunologic, hormonal, and environmental factors. A hypothesis that combines several of these factors proposes that genomic elements, the L1 retrotransposons, are instrumental in SLE pathogenesis. L1 retroelements are transcriptionally activated in SLE and produce two proteins, ORF1p and ORF2p, which are immunogenic and can drive type I interferon (IFN) production by producing DNA species that activate cytosolic DNA sensors. In addition, these two proteins reside in RNA-rich macromolecular assemblies that also contain well-known SLE autoantigens like Ro60. We surmise that cells expressing L1 will exhibit all the hallmarks of cells infected by a virus, resulting in a cellular and humoral immune response similar to those in chronic viral infections. However, unlike exogenous viruses, L1 retroelements cannot be eliminated from the host genome. Hence, dysregulated L1 will cause a chronic, but perhaps episodic, challenge for the immune system. The clinical and immunological features of SLE can be at least partly explained by this model. Here we review the support for, and the gaps in, this hypothesis of SLE and its potential for new diagnostic, prognostic, and therapeutic options in SLE.
No takes yet. Share an insight, caveat, or question.
Kennedy C. Ukadike (2021) conducted a review in Systemic lupus erythematosus (SLE). L1 retrotransposons was evaluated. Endogenous L1 retroelements are hypothesized to drive systemic lupus erythematosus pathogenesis by producing immunogenic proteins that activate cytosolic DNA sensors and type I interferon production.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: